Bristol-Myers drug successful in juvenile arthritis
15th Nov 2006, 05:02 GMT
Bristol-Myers Squibb has reported promising results for Orencia in an ongoing study which show improvement in children with active juvenile idiopathic arthritis, who have had an inadequate response to disease-modifying anti-rheumatic drugs.
Bristol-Myers drug successful in juvenile arthritis related news:
- Bristol arthritis drug effective in children: study — Reuters: Health
- Bristol arthritis drug effective in children: study (Reuters) — Yahoo! Health: Health News
- ORENCIA(R) (abatacept) Data Demonstrated Improvement In Children And Adolescents With Juvenile Idiopathic Arthritis — Health News from Medical News Today
- Adalimumab Proves Effective For Children With Juvenile Rheumatoid Arthritis — Health News from Medical News Today
- Scots go-ahead for arthritis drug — Scotsman.com News
- ACR: Humira Shows 'Profound' Benefit for Kids With Rheumatoid Arthritis — MedPage Today Pediatrics
- New schools' costs 'keep rising' — BBC News | England | Bristol | UK Edition
- FDA Expands Use of Abbott's Humira — Government/ Industry Regulation News from StratCenter.com
- Eves follows Bristol icon father — BBC Sport | Rugby Union | English | World Edition
- Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents — PR Newswire: All Releases
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol